Ibandronate

Identification

Name
Ibandronate
Accession Number
DB00710
Description

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.1,2 It is used to prevent and treat postmenopausal osteoporosis.11,12 Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.2

Ibandronate was granted FDA approval on 16 May 2003.11

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 319.2289
Monoisotopic: 319.094975119
Chemical Formula
C9H23NO7P2
Synonyms
  • ácido ibandrónico
  • Ibandronic acid
External IDs
  • R484

Pharmacology

Indication

For the treatment and prevention of osteoporosis in postmenopausal women.11,12

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Ibandronate is a nitrogen containing bisphosphonate used to treat and prevent osteoporosis in postmenopausal women.11,12 The therapeutic index is wide as overdoses are not especially toxic, and the duration of action is long as the half life can be up to 157 hours.11,12 Patients should be counselled regarding the risk of upper GI adverse reactions, hypocalcemia, musculoskeletal pain, osteonecrosis of the jaw, atypical fractures of the femur, and severe renal impairment.11,12

Mechanism of action

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis.5 Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act.5

Osteoclasts mediate resorption of bone.6 When osteoclasts bind to bone they form podosomes, ring structures of F-actin.6 Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption.6

Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate.7,3 These components are essential for post-translational prenylation of GTP-binding proteins like Rap1.7 The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis.7 ibandronate also activated caspase-3 which contribute to apoptosis.4

TargetActionsOrganism
AFarnesyl pyrophosphate synthase
inhibitor
Humans
AHydroxylapatite
antagonist
Humans
AGeranylgeranyl pyrophosphate synthase
inhibitor
Humans
Absorption

Oral ibandronate is 0.63% bioavailable.8 In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL.10 The Tmax is approximately 1 hour, while Cmax varies depending on dose.10

A 2mg intravenous dose of ibandronate has an AUC of 316ng*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng*h/mL.9

Volume of distribution

The apparent terminal volume of distribution of ibandronate is 90-368L in headlthy subjects and 103L in postmenopausal women with osteopenia.8,11,12

Protein binding

Ibandronate's protein binding in serum varies from 85.7-99.5% over a concentration of 0.5-10ng/mL,11 but is generally 86% across a concentration range of 20-2000ng/mL.12

Metabolism

Ibanronate is not metabolized in humans.11,12

Route of elimination

Ibandronate is predominantly eliminated in the urine and the unabsorbed drug is eliminated unchanged in the feces.8,11,12

Half-life

The half life of ibandronate in postmenopausal women ranges from 37-157 hours.11,12

Clearance

The total clearance of ibandronate is 84-160mL/min.11,12

Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Patients experiencing an overdose may present with hypocalcemia, hypophosphatemia, upset stomach, dyspepsia, esophagitis, and uclers.11,12 Oral overdose can be managed by giving patients milk or antacids to bind excess unabsorbed ibandronate.11 Overdoses can be managed by providing intravenous electrolytes and dialysis is not expected to remove excess drug from serum.11,12

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ibandronate Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acebutolol.
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Ibandronate.
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Acemetacin is combined with Ibandronate.
Acetylsalicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Ibandronate.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Acipimox.
AcrivastineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Acrivastine.
AcyclovirThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Ibandronate.
Adefovir dipivoxilThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Ibandronate.
AdenosineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Adenosine.
AjmalineThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ajmaline.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take on an empty stomach.
  • Take with a full glass of water. Do not take this medication with other liquids.

Products

Product Ingredients
IngredientUNIICASInChI Key
Ibandronate sodiumJ12U072QL0138926-19-9VBDRTGFACFYFCT-UHFFFAOYSA-M
Product Images
International/Other Brands
ADRONiL
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BondenzaInjection, solution3 mgIntravenousRoche Registration Limited2004-02-232013-05-13Eu
BondenzaTablet, film coated150 mgOralRoche Registration Limited2004-02-232013-05-13Eu
BondenzaInjection, solution3 mgIntravenousRoche Registration Limited2004-02-232013-05-13Eu
BondenzaTablet, film coated150 mgOralRoche Registration Limited2004-02-232013-05-13Eu
BondronatLiquidIntravenousHoffmann La Roche2004-05-312006-05-17Canada
BonivaInjection, solution3 mg/3mLIntravenousUNSPECIFIED2006-08-072006-08-07Us
BonivaTablet, film coated2.5 mg/1OralRoche Pharmaceuticals2006-07-202006-10-05Us
BonivaTablet, film coated150 mg/1OralGenentech, Inc.2005-03-24Not applicableUs
BonivaInjection, solution3 mg/3mLIntravenousPhysicians Total Care, Inc.2007-10-162010-06-30Us
BonivaInjection, solution3 mg/3mLIntravenousGenentech, Inc.2006-01-06Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate2 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate1 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonInjection, solution, concentrate6 mgIntravenousPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
IasibonTablet, film coated50 mgOralPharmathen S.A.2011-01-21Not applicableEu
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
M05BA06 — Ibandronic acidM05BB09 — Ibandronic acid and colecalciferol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic phosphonic acids and derivatives
Sub Class
Bisphosphonates
Direct Parent
Bisphosphonates
Alternative Parents
Organic phosphonic acids / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
1,3-aminoalcohol / Aliphatic acyclic compound / Amine / Bisphosphonate / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
UMD7G2653W
CAS number
114084-78-5
InChI Key
MPBVHIBUJCELCL-UHFFFAOYSA-N
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
IUPAC Name
{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid
SMILES
CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

References

Synthesis Reference

Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.

US20070179119
General References
  1. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28. [PubMed:30650219]
  2. Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH: A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res. 1993 Nov;8(11):1345-55. doi: 10.1002/jbmr.5650081109. [PubMed:8266826]
  3. Cao R, Chen CK, Guo RT, Wang AH, Oldfield E: Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. Proteins. 2008 Nov 1;73(2):431-9. doi: 10.1002/prot.22066. [PubMed:18442135]
  4. Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001 Jun 1;61(11):4418-24. [PubMed:11389070]
  5. Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. [PubMed:18214569]
  6. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T: Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997 May;20(5):399-404. [PubMed:9145236]
  7. Miwa A, Takezako N, Hayakawa H, Hayakawa M, Tominaga S, Yanagisawa K: YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation. Am J Hematol. 2012 Dec;87(12):1084-8. doi: 10.1002/ajh.23328. Epub 2012 Oct 9. [PubMed:23044853]
  8. Reginster JY, Neuprez A, Bruyere O: Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):941-51. doi: 10.1517/17425255.4.7.941. [PubMed:18624681]
  9. Croom KF, Scott LJ: Intravenous ibandronate: in the treatment of osteoporosis. Drugs. 2006;66(12):1593-601; discussion 1602-3. doi: 10.2165/00003495-200666120-00005. [PubMed:16956306]
  10. Barrett J, Worth E, Bauss F, Epstein S: Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004 Sep;44(9):951-65. doi: 10.1177/0091270004267594. [PubMed:15317823]
  11. FDA Approved Drug Products: Boniva Ibandronate Oral Tablets [Link]
  12. FDA Approved Drug Products: Boniva Ibandronate Intravenous Injection [Link]
Human Metabolome Database
HMDB0014848
PubChem Compound
60852
PubChem Substance
46508134
ChemSpider
54839
BindingDB
12577
RxNav
115264
ChEMBL
CHEMBL997
ZINC
ZINC000001533877
Therapeutic Targets Database
DAP001022
PharmGKB
PA10270
PDBe Ligand
BFQ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ibandronic_acid
PDB Entries
2f94 / 4umj / 6o9p / 6r4v
FDA label
Download (296 KB)
MSDS
Download (16 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionOsteopenia / Osteoporosis / Rheumatoid Arthritis1
4CompletedTreatmentLiver Cirrhosis1
4CompletedTreatmentOsteoporosis3
4CompletedTreatmentPain; Bone Neoplasms; Neoplasm Metastasis2
4CompletedTreatmentPost-Menopausal Osteopenia1
4CompletedTreatmentPostmenopausal Osteoporosis (PMO)16
4CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
4No Longer AvailableNot AvailablePostmenopausal Osteoporosis (PMO)1
4TerminatedTreatmentLung Cancers1
4TerminatedTreatmentOsteoporosis1

Pharmacoeconomics

Manufacturers
  • Hoffmann la roche inc
Packagers
  • Diversified Healthcare Services Inc.
  • F Hoffmann La Roche Ltd.
  • F Hoffmann-La Roche Ltd.
  • Physicians Total Care Inc.
  • Vetter Pharma Fertigung GmbH and Co. KG
Dosage Forms
FormRouteStrength
Tablet, coatedOral168.8 mg
Injection, solutionIntravenous; Parenteral3 MG
Solution, concentrateIntravenous2 MG
Injection, solution3 MG
Injection, solution, concentrateIntravenous; Parenteral2 MG
Injection, solution, concentrateIntravenous; Parenteral6 MG
Tablet, coatedOral50 MG
Tablet, coatedOral168.795 mg
Injection, solutionParenteral3 MG
Injection, solutionParenteral1 mg/mL
SolutionIntravenous6 mg
Injection, solution, concentrateIntravenous3 mg/3ml
Injection, solutionIntravenous3 mg
Tablet, film coatedOral150 mg
Tablet, coated50 mg
InjectionIntravenous6 mg/6ml
LiquidIntravenous
SolutionIntravenous2 mg/2ml
SolutionParenteral2 MG
Tablet, film coated50 mg
Injection, solution, concentrateIntravenous6 mg/6ml
SolutionParenteral6 MG
SolutionParenteral6 MG/6ML
Capsule, liquid filledOral150 mg
Injection, solutionIntravenous3 mg/3mL
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral2.5 mg/1
TabletOral150 MG
Tablet, coated150 mg
Injection, solutionParenteral3 MG/3ML
Injection3 mg/3ml
Injection, solutionParenteral3 MG/ML
Tablet
SolutionIntravenous3 mg
PowderOral150 mg
Injection, solution, concentrateIntravenous1 mg
Injection, solution, concentrateIntravenous2 mg
Injection, solution, concentrateIntravenous6 mg
Tablet, film coatedOral50 mg
PowderOral56.27 mg
Tablet, film coated150 mg
Tablet, coatedOral168.78 mg
PowderOral168.78 mg
Solution, concentrateIntravenous6 mg
InjectionIntravenous3 mg/3mL
TabletOral150 mg/1
SolutionParenteral2 MG/2ML
SolutionParenteral4 MG
Tablet, coatedOral150 mg
Prices
Unit descriptionCostUnit
Boniva 3 mg/3ml Kit Box524.22USD box
Boniva 3 mg/3 ml syringe504.06USD syringe
Boniva 3 150 mg tablet Disp Pack388.93USD disp
Boniva 150 mg tablet124.66USD tablet
Boniva 2.5 mg tablet4.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US4927814No1990-05-222012-03-17Us
CA2346662No2006-05-092019-10-01Canada
US7192938Yes2007-03-202023-11-06Us
US7718634Yes2010-05-182023-11-06Us
US7410957No2008-08-122023-05-06Us
US6294196No2001-09-252019-10-07Us
US6143326No2000-11-072017-04-21Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)113-115ChemSpider
water solubilityFreely solubleFDA Label
Predicted Properties
PropertyValueSource
Water Solubility13.4 mg/mLALOGPS
logP0.26ALOGPS
logP-2.5ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.66ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area138.53 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity71.16 m3·mol-1ChemAxon
Polarizability29.51 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9664
Blood Brain Barrier-0.5229
Caco-2 permeable-0.6012
P-glycoprotein substrateSubstrate0.6888
P-glycoprotein inhibitor INon-inhibitor0.8195
P-glycoprotein inhibitor IINon-inhibitor0.9838
Renal organic cation transporterNon-inhibitor0.9092
CYP450 2C9 substrateNon-substrate0.8376
CYP450 2D6 substrateNon-substrate0.7863
CYP450 3A4 substrateNon-substrate0.5504
CYP450 1A2 substrateNon-inhibitor0.832
CYP450 2C9 inhibitorNon-inhibitor0.8159
CYP450 2D6 inhibitorNon-inhibitor0.8987
CYP450 2C19 inhibitorNon-inhibitor0.8045
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9945
Ames testNon AMES toxic0.6527
CarcinogenicityNon-carcinogens0.683
BiodegradationNot ready biodegradable0.8346
Rat acute toxicity2.4278 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6061
hERG inhibition (predictor II)Non-inhibitor0.6622
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Poly(a) rna binding
Specific Function
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids...
Gene Name
FDPS
Uniprot ID
P14324
Uniprot Name
Farnesyl pyrophosphate synthase
Molecular Weight
48275.03 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. [PubMed:16932286]
  3. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603]
  4. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73. [PubMed:16892359]
Kind
Small molecule
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Catalyzes the trans-addition of the three molecules of IPP onto DMAPP to form geranylgeranyl pyrophosphate, an important precursor of carotenoids and geranylated proteins.
Gene Name
GGPS1
Uniprot ID
O95749
Uniprot Name
Geranylgeranyl pyrophosphate synthase
Molecular Weight
34870.625 Da
References
  1. Guo RT, Cao R, Liang PH, Ko TP, Chang TH, Hudock MP, Jeng WY, Chen CK, Zhang Y, Song Y, Kuo CJ, Yin F, Oldfield E, Wang AH: Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. Epub 2007 May 29. [PubMed:17535895]

Drug created on June 13, 2005 07:24 / Updated on August 13, 2020 01:03

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates